• EXO-NET customers growing across US, Europe and Asia
• Ovarian Cancer Screening test delivers outstanding diagnostic performance
• CAR-NK-exosome Proof-of-Concept achieved for killing breast cancer cells

INOVIQ delivered key development milestones across its exosome diagnostic, exosome therapeutic and SubB2M diagnostic programs. The company's exosome diagnostic for screening ovarian cancer delivered outstanding accuracy, its CAR-NK-exosome therapeutic achieved in vitro anti-cancer efficacy in breast cancer cells, and its neuCA15-3 breast cancer monitoring test showed disease specificity. These results further validate INOVIQ's technology platforms and substantially de-risk its diagnostic and therapeutic pipeline for breast and ovarian cancer. INOVIQ's EXO-NET business continues to grow, with Promega increasing the customer base to 41 during the quarter across academic/government, pharmaceutical/biotech and clinical laboratories/hospital customer types. Multiple evaluations of EXO-NET and NEURO-NET are being progressed for biomarker discovery and diagnostic development across cancer, cardiology and neurological diseases. INOVIQ also announced the successful completion of an in vitro proof-of-concept study for its exosome therapeutic for breast cancer, where CAR-NK-exosomes killed over 30% of triple-negative breast cancer cells. The company's neuCA15-3 test for monitoring breast cancer showed positive results for breast cancer, with the average CA15-3 concentration being five-fold greater than that observed in healthy individuals, and negative results for 97.4% of non-breast cancer samples.

INOVIQ had a cash balance of $9.476m at 31 December 2024. The company received a $1.018m R&D Tax Incentive refund during the quarter.

INOVIQ's priorities over the next 12 months are expanding its exosome isolation tools, partnering its lead SubB2M diagnostics, accelerating the development of its exosome diagnostics and therapeutics pipeline, and growing revenues from EXO-NET product sales and partnering.